Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.

Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Allison JJ, Anderson FA, Wyman A, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG.

J Bone Miner Res. 2018 May;33(5):763-772. doi: 10.1002/jbmr.3395. Epub 2018 Feb 26.

2.

Brief Report: Validation of a Definition of Flare in Patients With Established Gout.

Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, Vazquez-Mellado J, Hernández-Llinas H, Neogi T, Vargas-Santos AB, da Rocha Castelar-Pinheiro G, Amorim RBC, Uhlig T, Hammer HB, Eliseev M, Perez-Ruiz F, Cavagna L, McCarthy GM, Stamp LK, Gerritsen M, Fana V, Sivera F, Taylor W.

Arthritis Rheumatol. 2018 Mar;70(3):462-467. doi: 10.1002/art.40381. Epub 2018 Feb 6.

PMID:
29161469
3.

Differential stress induced c-Fos expression and identification of region-specific miRNA-mRNA networks in the dorsal raphe and amygdala of high-responder/low-responder rats.

Cohen JL, Ata AE, Jackson NL, Rahn EJ, Ramaker RC, Cooper S, Kerman IA, Clinton SM.

Behav Brain Res. 2017 Feb 15;319:110-123. doi: 10.1016/j.bbr.2016.11.015. Epub 2016 Nov 16.

4.

The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.

Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL.

Contemp Clin Trials. 2016 Sep;50:238-44. doi: 10.1016/j.cct.2016.08.016. Epub 2016 Aug 30.

5.

Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function.

Kennedy AJ, Rahn EJ, Paulukaitis BS, Savell KE, Kordasiewicz HB, Wang J, Lewis JW, Posey J, Strange SK, Guzman-Karlsson MC, Phillips SE, Decker K, Motley ST, Swayze EE, Ecker DJ, Michael TP, Day JJ, Sweatt JD.

Cell Rep. 2016 Sep 6;16(10):2666-2685. doi: 10.1016/j.celrep.2016.08.004. Epub 2016 Aug 25.

6.

A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material.

Danila MI, Outman RC, Rahn EJ, Mudano AS, Thomas TF, Redden DT, Allison JJ, Anderson FA, Anderson JP, Cram PM, Curtis JR, Fraenkel L, Greenspan SL, LaCroix AZ, Majumdar SR, Miller MJ, Nieves JW, Safford MM, Silverman SL, Siris ES, Solomon DH, Warriner AH, Watts NB, Yood RA, Saag KG.

Contemp Clin Trials Commun. 2016 Dec 15;4:14-24.

7.

Do long delay conditioned stimuli develop inhibitory properties?

Escobar M, Suits WT, Rahn EJ, Arcediano F.

Front Psychol. 2015 Oct 23;6:1606. doi: 10.3389/fpsyg.2015.01606. eCollection 2015.

8.

Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.

Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG.

Mol Pain. 2014 Apr 18;10:27. doi: 10.1186/1744-8069-10-27.

9.
10.

Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory.

Rahn EJ, Guzman-Karlsson MC, David Sweatt J.

Neurobiol Learn Mem. 2013 Oct;105:133-50. doi: 10.1016/j.nlm.2013.06.008. Epub 2013 Jun 22. Review.

11.

Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG.

Pharmacol Biochem Behav. 2011 Jun;98(4):493-502. doi: 10.1016/j.pbb.2011.02.024. Epub 2011 Mar 5.

12.

Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.

Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG.

AAPS J. 2010 Jun;12(2):147-57. doi: 10.1208/s12248-009-9170-8. Epub 2010 Feb 2.

13.

Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Rahn EJ, Hohmann AG.

Neurotherapeutics. 2009 Oct;6(4):713-37. doi: 10.1016/j.nurt.2009.08.002. Review.

14.

Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG.

J Pharmacol Exp Ther. 2008 Nov;327(2):584-91. doi: 10.1124/jpet.108.141994. Epub 2008 Jul 29.

15.

Supplemental Content

Support Center